help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiong, L. M.
Right arrow Articles by Fujita-Yamaguchi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiong, L. M.
Right arrow Articles by Fujita-Yamaguchi, Y.

Endocrinology, Vol 126, 2102-2109, Copyright © 1990 by Endocrine Society

ARTICLES

Characterization of human placental cytosolic adenosine 3',5'- monophosphate phosphodiesterase by inhibitors and insulin treatment

LM Xiong, TR LeBon and Y Fujita-Yamaguchi
Department of Molecular Genetics, Beckman Research Institute of the City of Hope, Duarte, California 91010.

To gain insight into the regulation of low Km cAMP phosphodiesterases (PDE) by insulin in human tissues, PDEs in human placenta were studied. Human placenta contained cAMP PDEs in particulate and cytosolic fractions. More than 99% of the total activity was localized in the cytosolic fraction. The cytosolic fraction exhibited at least four cyclic nucleotide PDEs when fractionated by DEAE-cellulose chromatography. The first form was a calmodulin-activated PDE which hydrolyzed both cGMP and cAMP. The second form was a high affinity cAMP PDE with a nonlinear kinetic characteristic, but was not inhibited by either cGMP or cilostamide (either compound is known to specifically inhibit rat insulin-sensitive cAMP PDE). The third form was a low Km cAMP PDE, but was only modestly sensitive to inhibition by cGMP or cilostamide. The fourth form was a cAMP PDE which showed high sensitivity to inhibition by cGMP or cilostamide. The IC50 values of the fourth form were comparable to those of rat adipose insulin- sensitive PDE. However, its Km for cAMP was 2 microM, which is about 10 times higher than that of the rat enzyme. Insulin treatment on placenta tissues stimulated at least two PDEs, the third and fourth forms. To our knowledge, this is the first report to describe insulin-sensitive cAMP PDEs in the cytosolic fraction of human placenta.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
N. Sato, K. Asai, S. Okumura, G. Takagi, R. P. Shannon, Y. Fujita-Yamaguchi, Y. Ishikawa, S. F. Vatner, and D. E. Vatner
Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure
Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1699 - H1705.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Kasuya, H. Goko, and Y. Fujita-Yamaguchi
Multiple Transcripts for the Human Cardiac Form of the cGMP-inhibited cAMP Phosphodiesterase
J. Biol. Chem., June 16, 1995; 270(24): 14305 - 14312.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society